Novavax Inc (NVAX.O)
28 Aug 2015
- A vaccine developed by Novavax Inc was shown to prevent a common respiratory viral infection in a mid-stage study, taking it one step closer to becoming the first vaccine for the virus that affects almost all American children.
Aug 10 - A vaccine developed by Novavax Inc was shown to prevent a common respiratory viral infection in a mid-stage study, taking it one step closer to becoming the first vaccine for the virus that affects almost all American children.
BRIEF-Novavax Inc says positive top-line data from RSV F-protein vaccine clinical trial in older adults
* Positive top-line data from phase 2 RSV F-protein vaccine clinical trial in older adults
- A Maryland-based biotech company believes it can solve a riddle that has baffled Big Pharma for decades: how to protect against a virus that infects almost every American child.
- Novavax Inc said its experimental Ebola vaccine induced a substantial immune response to the deadly infection in an early-stage trial involving 230 healthy adults.
* Stock hits more than 13-year high in morning trade (Adds details, executive comments, shares)
* Positive top-line data from phase 1 trial of ebola virus glycoprotein recombinant nanoparticle vaccine candidate adjuvanted with matrix-m
NEW YORK, June 23 - **Shares of Novavax extend gains in late afternoon trading on Tuesday; last up 11.7 percent at $11.12 after hitting its highest level since April 2002.
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (NVAX). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Novavax Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Provider : Thomson Reuters Stock Report
Provider : New Constructs, LLC
Provider : Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.